Article Text

Download PDFPDF

EP248/#551  A predictive value of CA-125 elimination of rate constant K(KELIM) on prognosis and duration of bevacizumab maintenance therapy in first platinum-sensitive recurrence of ovarian cancer
  1. Dong Won Hwang,
  2. Soo Jin Park and
  3. Hee Seung Kim
  1. Seoul National University Hospital, Obstetrics and Gynecology, Seoul, Korea, Republic of


Introduction To evaluate the predictive value of CA-125 ELIMination of Rate Constant K (KELIM) on prognosis and duration of long-term bevacizumab maintenance therapy (BMT) in first platinum-sensitive recurrence of ovarian cancer.

Methods We included patients with platinum-sensitive recurrence of ovarian cancer who underwent six cycles of paclitaxel-carboplatin-bevacizumab chemotherapy followed by BMT between 2015 and 2021. To predict the prognosis and duration of long-term BMT (≥10 cycles), we calculated KELIM scores after completion of three cycles of paclitaxel-carboplatin-bevacizumab. Then, we calculated the cut-off value of the KELIM score to predict progression-free interval ≥12 months.

Results A total of 96 patients were included, who consisted of 28 (29%) treated with secondary cytoreductive surgery (SCS) followed by chemotherapy, and 68 (71%) treated with chemotherapy alone. The cut-off value of the KELIM score for predicting PFI ≥12 months was 1.08. (AUC 0.82; sensitivity, 0.75; specificity, 0.76). Although SCS did not affect progression-free survival (PFS) and overall survival (OS), high-KELIM demonstrated better prognosis than low-KELIM in patients treated with SCS (PFS, median, 13.7 vs. 15.4 mons; p=0.04; OS, 21.7 vs. 28.8; p=0.006; figure 1), whereas there was no significant difference of PFS and OS according to the KELIM score in those treated with chemotherapy alone. Moreover, high-KELIM score was a favorable factor for long-term BMT in only those treated with SCS (adjusted odd ratio, 15; 95% confidence interval, 1.225–18.363).

Abstract EP248/#551 Figure 1

(A) Progression free survival (PFS), (B) overall survival (OS) of secondary cytoreductive surgery by paclitaxel-carboplatin-bevacizumab therapy group in the platinum sensitive recurrence of ovarian cancer patients according to KELIM score

Conclusion/Implications High-KELIM had a predictive value for better prognosis and long-term BMT in patients with first platinum-sensitive ovarian cancer who received paclitaxel-carboplatin-bevacizumab followed by BMT after SCS.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.